Cetuximab exhibits its antitumor activity by inhibiting EGFR-mediated tumor growth and stimulating NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC) activity to lyse tumor cells [12]. This evidence concerns the gene EGFR and neoplasm.